• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2.

作者信息

Opstal Tjerk S J, van Broekhoven Amber, Fiolet Aernoud T L, Mosterd Arend, Eikelboom John W, Nidorf Stefan M, Thompson Peter L, Budgeon Charley A, Bartels Louis, de Nooijer Ron, Bax Willem A, Tijssen Jan G P, El Messaoudi Saloua, Cornel Jan H

机构信息

Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands (T.S.J.O., A.v.B., S.E.M., J.H.C.).

Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands (T.S.J.O., J.H.C.).

出版信息

Circulation. 2022 Feb 22;145(8):626-628. doi: 10.1161/CIRCULATIONAHA.121.058233. Epub 2022 Feb 21.

DOI:10.1161/CIRCULATIONAHA.121.058233
PMID:35188792
Abstract
摘要

相似文献

1
Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2.秋水仙碱对慢性冠心病患者的长期疗效：来自LoDoCo2研究的见解
Circulation. 2022 Feb 22;145(8):626-628. doi: 10.1161/CIRCULATIONAHA.121.058233. Epub 2022 Feb 21.
2
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.稳定性冠心病患者低剂量秋水仙碱的疗效：LoDoCo2 试验的原理、设计和基线特征。
Am Heart J. 2019 Dec;218:46-56. doi: 10.1016/j.ahj.2019.09.011. Epub 2019 Oct 20.
3
[Colchicine in patients with coronary heart disease : LoDoCo2 trial].[冠心病患者使用秋水仙碱：LoDoCo2试验]
Internist (Berl). 2021 Mar;62(3):333-336. doi: 10.1007/s00108-021-00954-w. Epub 2021 Feb 12.
4
Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein.低剂量秋水仙碱对慢性冠状动脉疾病和高敏 C 反应蛋白升高患者炎症生物标志物、血脂、血细胞计数和肾功能的短期影响。
PLoS One. 2020 Aug 31;15(8):e0237665. doi: 10.1371/journal.pone.0237665. eCollection 2020.
5
Low-dose colchicine for coronary artery disease.低剂量秋水仙碱用于冠状动脉疾病
Med Lett Drugs Ther. 2021 Apr 5;63(1621):54-55.
6
Colchicine for secondary prevention of cardiovascular disease.秋水仙碱用于心血管疾病的二级预防。
Curr Atheroscler Rep. 2014 Mar;16(3):391. doi: 10.1007/s11883-013-0391-z.
7
Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease.短期秋水仙碱治疗对冠心病患者内皮功能的影响。
Int J Cardiol. 2019 Apr 15;281:35-39. doi: 10.1016/j.ijcard.2019.01.054. Epub 2019 Jan 15.
8
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome.秋水仙碱在慢性冠心病患者中的应用与既往急性冠状动脉综合征的关系。
J Am Coll Cardiol. 2021 Aug 31;78(9):859-866. doi: 10.1016/j.jacc.2021.06.037.
9
The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial.多年低剂量秋水仙碱暴露对肝肾功能和血肌酸激酶水平的影响：来自低剂量秋水仙碱 2 期临床试验（LoDoCo2）的安全性观察。
Clin Drug Investig. 2022 Nov;42(11):977-985. doi: 10.1007/s40261-022-01209-8. Epub 2022 Oct 8.
10
Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis.低剂量秋水仙碱治疗急性和慢性冠状动脉综合征的疗效：系统评价和荟萃分析。
Eur J Clin Invest. 2021 Apr;51(4):e13464. doi: 10.1111/eci.13464. Epub 2020 Dec 7.

引用本文的文献

1
Cardiorenal protective effects of Tanhuo decoction in acute myocardial infarction via regulating multi-target inflammation and metabolic signaling pathways.痰火方通过调节多靶点炎症和代谢信号通路对急性心肌梗死的心肺保护作用
Front Pharmacol. 2025 Mar 27;16:1555605. doi: 10.3389/fphar.2025.1555605. eCollection 2025.
2
Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack.秋水仙碱辅助治疗对冠心病合并急性痛风发作患者疾病控制、血清NALP3、可溶性细胞间黏附分子-1、基质金属蛋白酶-9和基质金属蛋白酶-13的影响。
J Med Biochem. 2025 Jan 24;44(1):46-54. doi: 10.5937/jomb0-51326.
3
Colchicine for the primary prevention of cardiovascular events.
秋水仙碱用于心血管事件的一级预防。
Cochrane Database Syst Rev. 2025 Feb 10;2(2):CD015003. doi: 10.1002/14651858.CD015003.pub2.
4
Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.免疫格局中的血小板信号传导：综合机制与临床治疗
Biomark Res. 2024 Dec 31;12(1):164. doi: 10.1186/s40364-024-00700-y.
5
"Anti-inflammatory Therapies in Atherosclerosis - Where are we going?".动脉粥样硬化中的抗炎疗法——我们将何去何从？
Curr Atheroscler Rep. 2024 Dec 19;27(1):19. doi: 10.1007/s11883-024-01267-7.
6
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials.秋水仙碱用于缺血性中风和动脉粥样硬化事件的二级预防：随机试验的荟萃分析
EClinicalMedicine. 2024 Oct 8;76:102835. doi: 10.1016/j.eclinm.2024.102835. eCollection 2024 Oct.
7
Lipoprotein(a) and High-Sensitivity C-Reactive Protein Compound the Risk of Hypoattenuating Leaflet Thickening After Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术后低信号瓣叶增厚的风险与脂蛋白(a)和高敏 C 反应蛋白相关。
J Am Heart Assoc. 2024 Nov 5;13(21):e035597. doi: 10.1161/JAHA.124.035597. Epub 2024 Oct 18.
8
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets.巨噬细胞中的信号通路：分子机制与治疗靶点。
MedComm (2020). 2023 Sep 11;4(5):e349. doi: 10.1002/mco2.349. eCollection 2023 Oct.
9
Prognostic value of high-sensitivity C-reactive protein in patients undergoing percutaneous coronary intervention with different glycemic metabolism status.高敏 C 反应蛋白对不同糖代谢状态行经皮冠状动脉介入治疗患者的预后价值。
Cardiovasc Diabetol. 2023 Aug 24;22(1):223. doi: 10.1186/s12933-023-01932-2.
10
Hypertensive heart disease: risk factors, complications and mechanisms.高血压性心脏病：危险因素、并发症及机制
Front Cardiovasc Med. 2023 Jun 5;10:1205475. doi: 10.3389/fcvm.2023.1205475. eCollection 2023.